

Table S1 Patient characteristics by treatment arm (ITT population)

	Moxifloxacin (n=354)	Comparator (n=376)	p value
<i>Enrolment visit</i>			
Males, n (%)	243 (68.6)	253 (67.3)	0.74*
Mean (SD) age (years)	63.8 (9.7)	62.6 (9.9)	0.08**
Mean (SD) years since CB diagnosis	12.2 (9.7)	12.8 (9.9)	0.45**
FEV ₁ % predicted, n (%)			0.81*
<50	149 (42.1)	159 (42.3)	
≥50	205 (57.9)	217 (57.7)	
Number of previous AECBs			0.79*
In previous year, n (%)			
<4	257 (72.6)	270 (71.8)	
≥4	97 (27.4)	106 (28.2)	
Mean (SD) smoking history (years)	37.5 (11.1)	37.7 (11.2)	0.80**
Previous smokers, n (%)	208 (58.8)	203 (54.0)	
Current smokers, n (%)	146 (41.2)	173 (46.0)	
Cardiopulmonary disease			0.59*
Not present, n (%)	301 (85.0)	324 (86.2)	
Present, n (%)	53 (15.0)	52 (13.8)	
<i>Randomisation visit</i>			
Days between onset of AECB symptoms and randomisation, n (%)†			0.54*
<4	249 (70.3)	275 (73.1)	
4–7	63 (17.8)	67 (17.8)	
>7	41 (11.6)	34 (9.0)	
Temperature (°C)			
Mean (SD)	37.6 (0.8)	37.6 (0.8)	0.31**
>38.5°C, n (%)	52 (14.7)	58 (15.4)	

	Moxifloxacin (n=354)	Comparator (n=376)	p value
<i>Enrolment visit</i>			
Respiration rate (breaths/min)			
Mean (SD)	21.5 (5.2)	21.9 (5.8)	0.35**
Steroid use, n (%)			0.36*
None‡	151 (42.7)	160 (42.6)	
Long term inhaled§	97 (27.4)	119 (31.6)	
Systemic and long term inhaled	55 (15.5)	57 (15.2)	
Systemic¶	51 (14.4)	40 (10.6)	

FEV₁, forced expiratory volume in 1 second; AECB, acute exacerbation of chronic bronchitis.

* χ^2 test.

***t* test.

†Not reported for one patient in the moxifloxacin arm.

‡Or no increase in steroid dosage.

§Administered for more than 2♦ months before randomisation.

¶Started at randomisation or increased dosage at randomisation if previously administered.